The role of iron deficiency in heart failure

Area of Science:

• Cardiology
• Nutritional Science
• Internal Medicine

Background:

• Iron deficiency (ID) is prevalent in approximately 50% of stable heart failure (HF) patients.
• ID in HF is multifactorial and linked to poor exercise tolerance, reduced quality of life, and increased mortality, independent of anemia.
• These factors significantly impact patient prognosis and daily functioning.

Purpose of the Study:

• To evaluate the efficacy of intravenous iron administration in patients with stable heart failure.
• To assess the impact of correcting iron deficiency on patient-reported outcomes and clinical endpoints.
• To determine if intravenous iron can mitigate the negative consequences associated with ID in HF.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Inclusion of studies focusing on intravenous iron supplementation in HF patients with ID.
• Assessment of primary outcomes including quality of life, exercise capacity, and hospitalization rates.

Main Results:

• Intravenous iron administration significantly improved quality of life scores in HF patients with ID.
• Patients receiving intravenous iron demonstrated enhanced exercise capacity compared to placebo.
• A notable reduction in hospitalization rates was observed in the group treated with intravenous iron.

Conclusions:

• Intravenous iron supplementation is a beneficial therapeutic strategy for patients with stable heart failure and iron deficiency.
• Correcting iron deficiency can alleviate key symptoms, improve functional capacity, and reduce healthcare utilization in HF patients.
• Further research should explore long-term outcomes and optimal iron repletion strategies in this population.